Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function

Loes M E Moolhuijsen, Jenny A Visser, Loes M E Moolhuijsen, Jenny A Visser

Abstract

Context: Anti-müllerian hormone (AMH) is produced by granulosa cells of small, growing follicles in the ovary. Serum AMH levels strongly correlate with the number of growing follicles, and therefore AMH has received increasing attention as a marker for ovarian reserve. This review summarizes recent findings and limitations in the application of serum AMH in ovarian reserve assessment.

Evidence acquisition: A PubMed search was conducted to find recent literature on the measurements and use of serum AMH as a marker for ovarian reserve.

Evidence synthesis: Serum AMH levels are measured to assess the "functional ovarian reserve," a term that is preferred over "ovarian reserve," since AMH levels reflect the pool of growing follicles that potentially can ovulate. Serum AMH levels are used in individualized follicle-stimulating hormone dosing protocols and may predict the risk of poor response or ovarian hyperstimulation syndrome but has limited value in predicting ongoing pregnancy. Serum AMH levels are studied to predict natural or disease-related age of menopause. Studies show that the age-dependent decline rates of AMH vary among women. The generalized implementation of serum AMH measurement has also led to an increase in diagnostic assays, including automated assays. However, direct comparison of results remains problematic.

Conclusion: Serum AMH remains the preferred ovarian reserve marker. However, the lack of an international standard for AMH limits comparison between AMH assays. Furthermore, little is known about endogenous and exogenous factors that influence serum AMH levels, which limits proper interpretation of AMH values in a clinical setting.

Keywords: AMH; AMH assays; fertility prediction; functional ovarian reserve; menopause; ovarian reserve.

© Endocrine Society 2020.

Figures

Figure 1.
Figure 1.
Anti-müllerian hormone expression and concentration in relation to folliculogenesis and ovarian reserve. (A) Anti-müllerian hormone (AMH) expression increases from the secondary stage onward until the small antral follicle stage. In preovulatory follicles, AMH is only expressed in cumulus granulosa cells surrounding the oocyte (dark pink layer). (B) With increasing age, the functional ovarian reserve decreases as a result of exhaustion of the primordial follicle pool. This leads to a decrease in the number of small antral follicles and consequently to a decrease in serum AMH levels, reaching undetectable levels at menopause. Figure created with Biorender.
Figure 2.
Figure 2.
Potential anti-müllerian hormone (AMH) isoforms and AMH assay characteristics. (A) Illustration of the possible AMH isoforms present in the circulation. The black dotted lines represent the cleavage sites at amino acids 229 and 451, respectively. The N-terminal proregion is shown in green, and the C-terminal mature region is shown in red. (B) Depicts the characteristics of the different AMH assays. The capture antibody is shown in purple, and the detector antibody is shown in orange. The assay type, limit of detection, and the measurement range of the different AMH assays are shown in the table below. Figure created with Biorender.

References

    1. Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519-527.
    1. te Velde ER, Scheffer GJ, Dorland M, Broekmans FJ, Fauser BC. Developmental and endocrine aspects of normal ovarian aging. Mol Cell Endocrinol. 1998;145(1-2):67-73.
    1. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum Reprod Update. 2014;20(3):370-385.
    1. Gleicher N, Weghofer A, Barad DH. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol. 2011;9:23.
    1. Findlay JK, Hutt KJ, Hickey M, Anderson RA. What is the “ovarian reserve”? Fertil Steril. 2015;103(3):628-630.
    1. Kevenaar ME, Meerasahib MF, Kramer P, et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology. 2006;147(7):3228-3234.
    1. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170-175.
    1. von Wolff M, Roumet M, Stute P, Liebenthron J. Serum anti-mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. Maturitas. 2020;134:34-40.
    1. Liebenthron J, Reinsberg J, van der Ven K, Saenger N, Kruessel JS, von Wolff M. Serum anti-müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation. Hum Reprod. 2019;34(12):2513-2522.
    1. Sermondade N, Sonigo C, Sifer C, et al. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertil Steril. 2019;111(2):357-362.
    1. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024.
    1. Lie Fong S, Visser JA, Welt CK, et al. Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012;97(12):4650-4655.
    1. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772.
    1. Du X, Ding T, Zhang H, et al. Age-specific normal reference range for serum anti-müllerian hormone in healthy Chinese Han women: a nationwide population-based study. Reprod Sci. 2016;23(8):1019-1027.
    1. Okunola OT, Ajenifuja OK, Loto MO, et al. Age-specific nomograms for follicle stimulating hormone and anti-mullerian hormone: a pilot study in Ile-Ife, Nigeria. Int J Reprod Biomed (Yazd). 2016;14(12):777-782.
    1. Tehrani FR, Mansournia MA, Solaymani-Dodaran M, Azizi F. Age-specific serum anti-müllerian hormone levels: estimates from a large population-based sample. Climacteric. 2014;17(5):591-597.
    1. Nelson SM, Messow MC, McConnachie A, et al. External validation of nomogram for the decline in serum anti-müllerian hormone in women: a population study of 15 834 infertility patients. Reprod Biomed Online. 2011;23(2):204-206.
    1. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimullerian hormone: a population study of 9601 infertility patients. Fertil Steril. 2011;95:736-741.
    1. Bozdag G, Calis P, Zengin D, Tanacan A, Karahan S. Age related normogram for antral follicle count in general population and comparison with previous studies. Eur J Obstet Gynecol Reprod Biol. 2016;206:120-124.
    1. Loy SL, Cheung YB, Fortier MV, et al. Age-related nomograms for antral follicle count and anti-mullerian hormone for subfertile Chinese women in Singapore. PLoS One. 2017;12(12):e0189830.
    1. Nelson SM, Aijun S, Ling Q, et al. Ethnic discordance in serum anti-müllerian hormone in healthy women: a population study from China and Europe. Reprod Biomed Online. 2020;40(3):461-467.
    1. Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI. Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril. 2014;101(1):199-207.
    1. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27(2):594-608.
    1. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y. Stable serum levels of anti-müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22(7):1837-1840.
    1. Gorkem U, Togrul C. Is there a need to alter the timing of anti-müllerian hormone measurement during the menstrual cycle? Geburtshilfe Frauenheilkd. 2019;79(7):731-737.
    1. Lambert-Messerlian G, Plante B, Eklund EE, Raker C, Moore RG. Levels of antimullerian hormone in serum during the normal menstrual cycle. Fertil Steril. 2016;105:208-213 e201.
    1. Melado L, Lawrenz B, Sibal J, et al. Anti-müllerian hormone during natural cycle presents significant intra and intercycle variations when measured with fully automated assay. Front Endocrinol (Lausanne). 2018;9:686.
    1. Overbeek A, Broekmans FJ, Hehenkamp WJ, et al. Intra-cycle fluctuations of anti-müllerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online. 2012;24(6):664-669.
    1. Bungum L, Tagevi J, Jokubkiene L, et al. The impact of the biological variability or assay performance on AMH measurements: a prospective cohort study with AMH tested on three analytical assay-platforms. Front Endocrinol (Lausanne). 2018;9:603.
    1. Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45(5):685-698.
    1. Pepinsky RB, Sinclair LK, Chow EP, et al. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J Biol Chem. 1988;263(35):18961-18964.
    1. Nachtigal MW, Ingraham HA. Bioactivation of mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci U S A 1996;93:7711-7716.
    1. Donahoe PK. Müllerian inhibiting substance in reproduction and cancer. Mol Reprod Dev. 1992;32(2):168-172.
    1. Gassner D, Jung R. First fully automated immunoassay for anti-müllerian hormone. Clin Chem Lab Med. 2014;52(8):1143-1152.
    1. Hyldgaard J, Bor P, Ingerslev HJ, Tørring N. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. Reprod Biol Endocrinol. 2015;13:107.
    1. Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimullerian hormone assays. Fertil Steril. 2015;104:1016-1021 e1016.
    1. Pearson K, Long M, Prasad J, Wu YY, Bonifacio M. Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation II manual ELISA. Reprod Biol Endocrinol. 2016;14:8.
    1. van Helden J, Weiskirchen R. Performance of the two new fully automated anti-müllerian hormone immunoassays compared with the clinical standard assay. Hum Reprod. 2015;30(8):1918-1926.
    1. Pankhurst MW, McLennan IS. Human blood contains both the uncleaved precursor of anti-mullerian hormone and a complex of the NH2- and COOH-terminal peptides. Am J Physiol Endocrinol Metab. 2013;305(10):E1241-E1247.
    1. di Clemente N, Jamin SP, Lugovskoy A, et al. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta. Mol Endocrinol. 2010;24(11):2193-2206.
    1. Wissing ML, Mikkelsen AL, Kumar A, et al. Associations of different molecular forms of antimullerian hormone and biomarkers of polycystic ovary syndrome and normal women. Fertil Steril. 2019;112:149-155 e141.
    1. Amer SAKS, James C, Al-Hussaini TK, Mohamed AA. Assessment of circulating anti-müllerian hormone in women using hormonal contraception: a systematic review. J Womens Health (Larchmt). 2020;29(1):100-110.
    1. Landersoe SK, Forman JL, Birch Petersen K, et al. Ovarian reserve markers in women using various hormonal contraceptives. Eur J Contracept Reprod Health Care. 2020;25(1):65-71.
    1. Moslehi N, Shab-Bidar S, Ramezani Tehrani F, Mirmiran P, Azizi F. Is ovarian reserve associated with body mass index and obesity in reproductive aged women? A meta-analysis. Menopause. 2018;25(9):1046-1055.
    1. Merhi Z, Buyuk E, Berger DS, et al. Leptin suppresses anti-mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF. Hum Reprod. 2013;28(6):1661-1669.
    1. Ding X, Kou X, Zhang Y, Zhang X, Cheng G, Jia T. Leptin siRNA promotes ovarian granulosa cell apoptosis and affects steroidogenesis by increasing NPY2 receptor expression. Gene. 2017;633:28-34.
    1. Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-müllerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012;97(7):2450-2455.
    1. Dennis NA, Houghton LA, Pankhurst MW, Harper MJ, McLennan IS. Acute supplementation with high dose vitamin D3 increases serum anti-mullerian hormone in young women. Nutrients. 2017;9(7):719.
    1. Xu J, Hennebold JD, Seifer DB. Direct vitamin D3 actions on rhesus macaque follicles in three-dimensional culture: assessment of follicle survival, growth, steroid, and antimullerian hormone production. Fertil Steril. 2016;106:1815-1820 e1811.
    1. Xu J, Lawson MS, Xu F, et al. Vitamin D3 regulates follicular development and intrafollicular vitamin D biosynthesis and signaling in the primate ovary. Front Physiol. 2018;9:1600.
    1. Merhi Z, Doswell A, Krebs K, Cipolla M. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab. 2014;99(6):E1137-E1145.
    1. Krishnan AV, Moreno J, Nonn L, et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007;103(3-5):694-702.
    1. Balasch J, Gratacós E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Fetal Diagn Ther. 2011;29(4):263-273.
    1. Depmann M, Eijkemans MJC, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta- analysis. J Clin Endocrinol Metab. 2018;103:3593-3600.
    1. Kim C, Slaughter JC, Wang ET, et al. Anti-müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas. 2017;102:18-25.
    1. Finkelstein JS, Lee H, Karlamangla A, et al. Antimullerian hormone and impending menopause in late reproductive age: the study of women’s health across the nation. J Clin Endocrinol Metab. 2020;105:1862-1871.
    1. Bertone-Johnson ER, Manson JE, Purdue-Smithe AC, et al. Anti-müllerian hormone levels and incidence of early natural menopause in a prospective study. Hum Reprod. 2018;33(6):1175-1182.
    1. de Kat AC, van der Schouw YT, Eijkemans MJ, et al. Back to the basics of ovarian aging: a population-based study on longitudinal anti-müllerian hormone decline. BMC Med. 2016;14(1):151.
    1. de Kat AC, van der Schouw YT, Eijkemans MJC, Broer SL, Verschuren WMM, Broekmans FJM. Can menopause prediction be improved with multiple AMH measurements? Results from the prospective Doetinchem cohort study. J Clin Endocrinol Metab. 2019;104(11):5024-5031.
    1. Ramezani Tehrani F, Bidhendi Yarandi R, Solaymani-Dodaran M, Tohidi M, Firouzi F, Azizi F. Improving prediction of age at menopause using multiple anti-mullerian hormone measurements: the Tehran lipid-glucose study. J Clin Endocrinol Metab. 2020;105:1589-1598.
    1. Gohari MR, Ramezani Tehrani F, Chenouri S, Solaymani-Dodaran M, Azizi F. Individualized predictions of time to menopause using multiple measurements of antimüllerian hormone. Menopause. 2016;23(8):839-845.
    1. Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? Reprod Biomed Online. 2017;34(4):345-353.
    1. Broer SL, Dolleman M, van Disseldorp J, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013;100:420-429 e427.
    1. Broer SL, van Disseldorp J, Broeze KA, et al. ; IMPORT study group . Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26-36.
    1. Lensen SF, Wilkinson J, Leijdekkers JA, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev. 2018;2:CD012693.
    1. Friis Petersen J, Lokkegaard E, Andersen LF, et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Hum Reprod Open. 2019;2019:hoz003.
    1. Luo W, Mao P, Zhang L, Chen X, Yang Z. Assessment of ovarian reserve by serum anti-müllerian hormone in patients with systemic lupus erythematosus: a meta-analysis. Ann Palliat Med. 2020;9(2):207-215.
    1. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(9):1534-1538.
    1. Henes M, Froeschlin J, Taran FA, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet’s disease and spondyloarthritis on anti-müllerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709-1712.
    1. Eudy AM, McDaniel G, Hurd WW, Clowse MEB. Fertility and ovarian reserve among women with rheumatoid arthritis. J Rheumatol. 2019;46(5):455-459.
    1. Ferreira GRV, Tomioka RB, Aikawa NE, et al. Ovarian reserve in young juvenile idiopathic arthritis patients. Mod Rheumatol. 2019;29(3):447-451.
    1. Erol O, Parlak M, Ellidağ HY, et al. Serum anti-müllerian hormone levels in euthyroid adolescent girls with Hashimoto’s thyroiditis: relationship to antioxidant status. Eur J Obstet Gynecol Reprod Biol. 2016;203:204-209.
    1. Özalp Akın E, Aycan Z. Evaluation of the ovarian reserve in adolescents with Hashimoto’s thyroiditis using serum anti-müllerian hormone levels. J Clin Res Pediatr Endocrinol. 2018;10(4):331-335.
    1. Pirgon O, Sivrice C, Demirtas H, Dundar B. Assessment of ovarian reserve in euthyroid adolescents with Hashimoto thyroiditis. Gynecol Endocrinol. 2016;32(4):306-310.
    1. Tuten A, Hatipoglu E, Oncul M, et al. Evaluation of ovarian reserve in Hashimoto’s thyroiditis. Gynecol Endocrinol. 2014;30(10):708-711.
    1. Kuroda K, Uchida T, Nagai S, et al. Elevated serum thyroid-stimulating hormone is associated with decreased anti-müllerian hormone in infertile women of reproductive age. J Assist Reprod Genet. 2015;32(2):243-247.
    1. Weghofer A, Barad DH, Darmon S, Kushnir VA, Gleicher N. What affects functional ovarian reserve, thyroid function or thyroid autoimmunity? Reprod Biol Endocrinol. 2016;14(1):26.
    1. Bahri S, Tehrani FR, Amouzgar A, et al. Overtime trend of thyroid hormones and thyroid autoimmunity and ovarian reserve: a longitudinal population study with a 12-year follow up. BMC Endocr Disord. 2019;19(1):47.
    1. Chen CW, Huang YL, Tzeng CR, Huang RL, Chen CH. Idiopathic low ovarian reserve is associated with more frequent positive thyroid peroxidase antibodies. Thyroid. 2017;27(9):1194-1200.
    1. Rao M, Wang H, Zhao S, et al. Subclinical hypothyroidism is associated with lower ovarian reserve in women aged 35 years or older. Thyroid. 2020;30(1):95-105.
    1. Kuroda M, Kuroda K, Segawa T, et al. Levothyroxine supplementation improves serum anti-müllerian hormone levels in infertile patients with Hashimoto’s thyroiditis. J Obstet Gynaecol Res. 2018;44(4):739-746.
    1. Magri F, Schena L, Capelli V, et al. Anti-mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. Reprod Biol Endocrinol. 2015;13(1):106.
    1. Dorman JS, Steenkiste AR, Foley TP, et al. ; Familial Autoimmune and Diabetes (FAD) Study . Menopause in type 1 diabetic women: is it premature? Diabetes. 2001;50(8):1857-1862.
    1. Soto N, Iñiguez G, López P, et al. Anti-mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod. 2009;24(11):2838-2844.
    1. Kim C, Karvonen-Gutierrez C, Kong S, et al. Antimüllerian hormone among women with and without type 1 diabetes: the epidemiology of diabetes interventions and complications study and the Michigan Bone Health and Metabolism Study. Fertil Steril. 2016;106(6):1446-1452.
    1. Yarde F, Spiering W, Franx A, et al. ; OVADIA Study Group . Association between vascular health and ovarian ageing in type 1 diabetes mellitus. Hum Reprod. 2016;31(6):1354-1362.
    1. Yarde F, van der Schouw YT, de Valk HW, et al. ; OVADIA study group . Age at menopause in women with type 1 diabetes mellitus: the OVADIA study. Hum Reprod. 2015;30(2): 441-446.
    1. Zhong Y, Lin Y, Cheng X, et al. GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer. J Cancer. 2019;10(18):4278-4285.
    1. Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017;87:58-64.
    1. Xue C, Wei W, Sun P, et al. Pretreatment anti-mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019;173(3):619-628.
    1. Passildas J, Collard O, Savoye AM, et al. Impact of chemotherapy-induced menopause in women of childbearing age with non-metastatic breast cancer - preliminary results from the MENOCOR study. Clin Breast Cancer. 2019;19(1):e74-e84.
    1. Lee DY, Park YH, Lee JE, Choi D. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. Breast Cancer Res Treat. 2018;171(3):649-656.
    1. Decanter C, Cloquet M, Dassonneville A, D’Orazio E, Mailliez A, Pigny P. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reprod Biomed Online. 2018;36(6):711-718.
    1. Kim HA, Choi J, Park CS, et al. ; The ASTRRA trial investigators . Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery. Endocr Connect. 2018;7(8):949-956.
    1. Cameron K, Sammel MD, Prewitt M, Gracia C. Differential rates of change in measures of ovarian reserve in young cancer survivors across the reproductive lifespan. J Clin Endocrinol Metab. 2019;104(5):1813-1822.
    1. Su HI, Kwan B, Whitcomb BW, et al. Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH. J Clin Endocrinol Metab. 2020;105(8).
    1. Yaish I, Azem F, Gutfeld O, et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study. Thyroid. 2018;28(4):522-527.
    1. Evranos B, Faki S, Polat SB, Bestepe N, Ersoy R, Cakir B. Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study. Thyroid. 2018;28(12):1702-1707.
    1. van Velsen EFS, Visser WE, van den Berg SAA, et al. Longitudinal analysis of the effect of radioiodine therapy on ovarian reserve in females with differentiated thyroid cancer. Thyroid. 2020;30(4):580-587.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever